Brain Barriers as Targets in Pathologies and Therapy

Author(s): Maria Deli, Andrej Kovac

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 13 , 2020

Become EABM
Become Reviewer

[1]
Toth AE, Holst MR, Nielsen MS. Vesicular transport machinery in brain endothelial cells: what we know and what we do not. Curr Pharm Des 2020; 26(13): 1405-16.
[2]
Curtaz CJ, Schmitt C, Blecharz-Lang KG, Roewer N, Wöckel A, Burek M. Circulating MicroRNAs and blood-brain-barrier function in breast cancer metastasis. Curr Pharm Des 2020; 26(13): 1417-27.
[3]
de Trizio I, Errede M, d’Amati A, Girolamo F, Virgintino D. Expression of P-gp in glioblastoma: what we can learn from brain development. Curr Pharm Des 2020; 26(13): 1428-37.
[4]
Banks WA. The blood-brain barrier interface in diabetes mellitus: dysfunctions, mechanisms, and approaches to treatment. Curr Pharm Des 2020; 26(13): 1438-47.
[5]
Hanes J, Dobakova E, Majerova P. Brain drug delivery: overcoming the blood-brain barrier to treat tauopathies. Curr Pharm Des 2020; 26(13): 1448-65.
[6]
Morofuji Y, Nakagawa S. Drug development for central nervous system diseases using in vitro blood-brain barrier models and drug repositioning. Curr Pharm Des 2020; 26(13): 1466-85.
[7]
Tóth ME, Dukay B, Hoyk Z, Sántha M. Cerebrovascular changes and neurodegeneration related to hyperlipidemia: characteristics of the human apob-100 transgenic mice. Curr Pharm Des 2020; 26(13): 1486-94.
[8]
Cavaco M, Valle J, da Silva R, et al. DPepH3, an improved peptide shuttle for receptor-independent transport across the blood-brain barrier. Curr Pharm Des 2020; 26(13): 1495-506.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 13
Year: 2020
Page: [1403 - 1404]
Pages: 2
DOI: 10.2174/138161282613200506134601

Article Metrics

PDF: 22
HTML: 2